+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

In vitro interaction of some drug combinations to inhibit rapidly growing mycobacteria isolates from cats and dogs and these isolates' susceptibility to cefovecin and clofazimine



In vitro interaction of some drug combinations to inhibit rapidly growing mycobacteria isolates from cats and dogs and these isolates' susceptibility to cefovecin and clofazimine



Australian Veterinary Journal 93(1-2): 40-45



To investigate whether selected drug combinations used to treat rapidly growing mycobacteria (RGM) have drug-drug interactions that affect efficacy and to investigate each isolate's susceptibility to cefovecin and clofazimine, individually. In vitro susceptibility testing of bacterial isolates. Initially, five feline isolates and one canine isolate from both Mycobacterium fortuitum and M. smegmatis clusters (n = 12) underwent microbroth susceptibility testing to individual drugs to establish minimum inhibitory concentrations (MIC) of cefovecin, ciprofloxacin, clarithromycin, clofazimine, doxycycline, enrofloxacin, trimethoprim and sulfanilamide (the latter two as a combination). Checkerboard assays were then performed for susceptible M. smegmatis isolates for the following combinations: clarithromycin (one isolate only) versus enrofloxacin, clarithromycin vs doxycycline, clarithromycin vs trimethoprim/sulfanilamide; enrofloxacin vs doxycycline (six isolates); enrofloxacin vs trimethoprim/sulfanilamide (six isolates). Susceptible M. fortuitum isolates were tested against enrofloxacin versus doxycycline (four isolates only). All six M. fortuitum isolates were susceptible to enrofloxacin, but only four of six were susceptible to doxycycline. All six M. smegmatis isolates were susceptible to doxycycline, enrofloxacin and trimethoprim/sulfanilamide. A single isolate from the 12, a M. smegmatis isolate, was susceptible to clarithromycin. The fractional inhibitory concentration of each drug ranged from 0.64 to 1.84, indicating that neither synergism nor antagonism was evident. All 12 isolates were resistant to cefovecin. The clofazimine MIC50 to inhibit isolate growth was approximately 3.3 μg/mL for both strains. Drugs commonly used for treatment of RGM, when tested as combinations, do not appear to antagonise one another in vitro. Cefovecin is not efficacious for treatment of RGM infections.

(PDF emailed within 0-6 h: $19.90)

Accession: 058086659

Download citation: RISBibTeXText

PMID: 25622709

DOI: 10.1111/avj.12279


Related references

Susceptibility of rapidly growing mycobacteria and Nocardia isolates from cats and dogs to pradofloxacin. Veterinary Microbiology 153(3-4): 240-245, 2012

Susceptibility of rapidly growing mycobacteria and Nocardia isolates from cats and dogs to pradofloxacin pradofloxacin. 2011

Drug Susceptibility Testing of 31 Antimicrobial Agents on Rapidly Growing Mycobacteria Isolates from China. Biomed Research International 2015: 419392, 2016

In vitro antimicrobial susceptibility testing of rapidly growing mycobacteria using the tablet diffusion method: Resistance pattern of Norwegian Mycobacterium fortuitum and Mycobacterium chelonae isolates. APMIS 101(1): 27-32, 1993

In vitro activity of linezolid against isolates of rapidly growing mycobacteria. Abstracts of the General Meeting of the American Society for Microbiology 100: 654, 2000

Susceptibility of rapidly growing mycobacteria isolated from cats and dogs, to ciprofloxacin, enrofloxacin and moxifloxacin. Veterinary Microbiology 147(1-2): 113-118, 2011

In vitro activity of a novel des-fluoro quinolone BMS-284756 against rapidly growing mycobacteria and Nocardia isolates. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 175, 2001

In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. Antimicrobial Agents and ChemoTherapy 51(5): 1849-1851, 2007

In vitro activity of a novel des-fluoro(6) quinolone, garenoxacin (BMS-284756), against rapidly growing mycobacteria and Nocardia isolates. Journal of Antimicrobial ChemoTherapy 50(1): 140-142, 2002

In vitro activity of clofazimine against rapidly growing nonchromogenic mycobacteria. Antimicrobial Agents and ChemoTherapy 29(5): 951-952, 1986

In Vitro Comparison of Ertapenem, Meropenem, and Imipenem against Isolates of Rapidly Growing Mycobacteria and Nocardia by Use of Broth Microdilution and Etest. Journal of Clinical Microbiology 54(6): 1586-1592, 2017

In vitro drug susceptibility of 40 international reference rapidly growing mycobacteria to 20 antimicrobial agents. International Journal of Clinical and Experimental Medicine 8(9): 15423-15431, 2015

Orbital abscess bacterial isolates and in vitro antimicrobial susceptibility patterns in dogs and cats. Veterinary Ophthalmology 12(2): 91-96, 2009

Antifungal drug susceptibility and phylogenetic diversity among Cryptococcus isolates from dogs and cats in North America. Journal of Clinical Microbiology 52(6): 2061-2070, 2015

Prevalence of erm methylase genes in clinical isolates of non-pigmented, rapidly growing mycobacteria. Clinical Microbiology and Infection 15(10): 919-923, 2009